Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(75.0%)

Phase 3

1(25.0%)

4Total

N/A(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04442048Phase 3Completed

Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

Role: collaborator

NCT03249727Not ApplicableTerminated

Analysis of Natural Killer Cell Activity (NKA) in Whole Blood in High Risk Subjects Undergoing Colonoscopy

Role: lead

NCT03242265Not ApplicableTerminated

Measurement of Natural Killer Cell Activity in Whole Blood in Men Being Screened for Prostate Cancer With Biopsy

Role: lead

NCT03422120Completed

Human Blood Specimen Collection to Evaluate Immune Cell Function

Role: collaborator

NCT02291198Not ApplicableCompleted

Measurement of NK Cell Activity in Whole Blood in Subjects Being Screened for Colorectal Cancer Using Colonoscopy

Role: lead

All 5 trials loaded